Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Discovering February 2025's Promising Penny Stocks On US Exchanges

In This Article:

As the S&P 500 hovers near record highs and Treasury yields drop following recent retail sales data, U.S. markets continue to capture investor attention with a mix of optimism and caution. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing segment for those seeking unique investment opportunities. Despite the term's historical connotations, these stocks can offer hidden value when supported by strong financials and growth potential. This article will explore three such penny stocks that stand out for their balance sheet resilience and potential for future success.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.8964

$6.3M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$131.87M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.81

$46.67M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.84

$86.14M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.395

$46.2M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8977

$80.89M

★★★★★☆

Smith Micro Software (NasdaqCM:SMSI)

$1.40

$24.65M

★★★★★☆

PHX Minerals (NYSE:PHX)

$4.17

$154.8M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.61

$382.26M

★★★★☆☆

Click here to see the full list of 710 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Ikena Oncology

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Ikena Oncology, Inc. is a U.S.-based oncology company focused on developing differentiated therapies targeting cancer growth, spread, and resistance, with a market cap of $70.46 million.

Operations: Ikena Oncology, Inc. currently does not report any revenue segments.

Market Cap: $70.46M

Ikena Oncology, with a market cap of US$70.46 million, is currently pre-revenue and unprofitable, lacking significant revenue streams. Despite this, it has a stable cash runway for over a year due to its strong short-term assets of US$141.5 million exceeding liabilities. The company is debt-free and recently announced a reverse merger with Inmagene Biopharmaceuticals, expected to close mid-2025, which could provide strategic opportunities. However, the management team has limited experience with an average tenure of 1.3 years and the company faces challenges in achieving profitability within the next three years.

NasdaqGM:IKNA Debt to Equity History and Analysis as at Feb 2025
NasdaqGM:IKNA Debt to Equity History and Analysis as at Feb 2025

Marchex

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Marchex, Inc. is a conversation intelligence company offering conversational analytics and related solutions across the United States, Canada, and internationally with a market cap of $86.63 million.